価格
始める
米国企業
Lunai Bioworks Inc.
Raw
Lunai Bioworks Inc.
【LNAI】
時価総額
$3173.9万
PER
マルチオミクス解析とAI診断プラットフォームの新興企業。液体生検を含むマルチモーダル解析とOxford Nanopore採用のシーケンシングサービスを展開。GEDi Cubeを2024年2月13日に買収、CLIA/ISO認証ラボ設置計画。オランダを起点にEMEA・米国展開。
マイリストに追加
マイリストに追加
株価
業績
サマリーテーブルに戻る
十億
百万
千
USD
年次
四半期
Download CSV
2012年
3月31日
2013年
3月31日
2014年
12月31日
2016年
6月30日
2017年
6月30日
2018年
6月30日
2019年
6月30日
2021年
6月30日
2022年
6月30日
2023年
6月30日
2024年
6月30日
NET LOSS
-29,945
-37,589
-2,370,883
-1,735,239
-2,392,830
471
-18,016,480
-26,723,607
-113,433,392
-39,684,056
-80,650,172
Depreciation and amortization
-
-
45,201
27,395
14,528
3
71,709
123,535
123,590
113,496
121,859
Change in fair value of contingent consideration
-
-
-
-
-
-
-
-3,048,033
3
-
5
Loss on extinguishment of debt
-
-
-
-
-
-
-
-
-
-
-1,303,578
Non-cash stock-based compensation expense
-
-
-
-
-
-
-
-
-
-
5
Non-cash restricted shares issued for services rendered
-
-
-
-
-
-
-
-
-
228,000
5
Intangible asset impairment
-
-
-
-
-
-
-
-
-
-
43
Goodwill impairment
-
-
-
-
-
-
-
-
-
-
12
Amortization of discount on note payable
-
-
-
-
-
-
-
-296,505
-297,212
-348,621
580,605
Insurance receivable
-
-
-
-
-471,641
-108,005
-119,831
-342
-1,594
-46
1
Prepaid expenses/deposits
-
-
-
-
19,828
138,841
160,940
-733,739
-461,310
-1,070,249
-1,082,267
Accounts payable
-
-
162,950
574,975
-652,785
119,575
-29,946
-272,318
1
4
4
Other current liabilities
-
-
-
-
-
-
-
30,004
24,056
-54,060
-
Operating leases, net
-
-
-
-
-
-
-
-
-
-27,224
11,284
Accrued expenses
-
-
-
-
-
-
-
-
-
-578,809
5
NET CASH USED IN OPERATING ACTIVITIES
-24,945
-30,092
-2,034,175
-1,472,289
-
-4,338,269
-8,507,341
-20,610,723
-15,732,336
-11,774,549
-10,971,430
Notes receivable prior to acquisition
-
-
-
-
-
-
-
-
-
-
1
Cash received from acquisition, net
-
-
-
-
-
-
-
-
-
-
65,851
Purchase of property and equipment
-
-
-
-
-
30,000
716,669
48,892
5,156
29,774
70,430
NET CASH USED IN INVESTING ACTIVITIES
-13,219
-13,219
-1,952,034
1
-
-575,732
-716,669
-48,892
-5,156
-29,774
-1,260,179
Repayments of finance agreement
-
-
-
-
-
-
-
-
-
-
870,073
Proceeds from exercise of warrants
-
-
-
-
-
-
6
82,056
130,000
2
341,865
Proceeds from private placements
-
-
-
-
-
-
-
5
-
4
3
Proceeds from issuance of promissory notes
-
-
-
-
-
-
-
-
-
-
4
Proceeds from convertible notes payable
-
-
-
-
413,670
-
-
-
-
-
4
NET CASH PROVIDED BY FINANCING ACTIVITIES
38,500
75,000
7
-
-
17
6
33
4
5
11
Effect of exchange rates on cash
-
-
-
-
-
-
-
-
-5,240
-8,395
60,141
NET INCREASE (DECREASE) IN CASH
-
-
-
-
-
-
-
12
-11,492,268
-7,297,662
-1,654,013
Interest
-
-
-
-
-
-
43
89,224
79,716
352,334
20,128
Income Taxes
-
-
-
-
64,003
-
-
37
34
-
-
Finance agreement entered into in exchange for prepaid assets
-
-
-
-
-
-
-
607,250
666,875
1
906,834
Conversion of note payable for issuance of preferred stock
-
-
-
-
-
-
-
-
-
-
2
Note payable settled through non-cash exercise of warrants
-
-
-
-
-
-
-
-
-
-
2
Debt discount related to notes payable
-
-
-
-
-
-
-
-
-
-
339,342
Common shares issued upon acquisition
-
-
-
-
-
-
-
-
-
-
136
Contingent consideration issued upon acquisition
-
-
-
-
-
-
-
-
-
-
21
Common shares issued upon settlement of debt
-
-
-
-
-
-
-
-
-
-
10
Earn out shares issued in settlement of contingent liability
-
-
-
-
-
-
-
-
-
-
4
Options issued in settlement of debt
-
-
-
-
-
-
-
-
-
-
489,000
Settlement of notes payable
-
-
-
-
-
-
-
-
-
-
418,503